SCHEMBL23250453

SCHEMBL23250453

Fc1cc(F)c(C2CC2)cc1Br

nearest known ligand 0.47

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 10/20 0.47
KDM1B Q8NB78 6/20 0.47
KCNH2 Q12809 4/20 0.47
OPRL1 P41146 4/20 0.34
IDO1 P14902 4/20 0.33
AKR1A1 P14550 1/20 0.31
AKR1B1 P15121 1/20 0.31
CHRNB2 P17787 1/20 0.30
CHRNB4 P30926 1/20 0.30
CHRNA3 P32297 1/20 0.30
CHRNA4 P43681 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31424337 1.00 KDM1A (0.47) KDM1AKDM1BKCNH2OPRL1IDO1
SCHEMBL27090011 0.81 KDM1A (0.39) KDM1AKDM1BKCNH2IDO1AKR1B1
SCHEMBL4568233 0.77 KDM1A (0.43) KDM1AKDM1BKCNH2
SCHEMBL27447794 0.77 KDM1A (0.43) KDM1AKDM1BKCNH2IDO1CHRNB2
SCHEMBL24546532 0.77 KDM1A (0.36) KDM1AKDM1BKCNH2IDO1AKR1A1
SCHEMBL9732012 0.75 KDM1A (0.50) KDM1AKDM1BKCNH2IDO1CHRNB2
SCHEMBL24746185 0.75 NOTUM (0.38) KDM1AKDM1BKCNH2AKR1B1
SCHEMBL9731123 0.75 KDM1A (0.50) KDM1AKDM1BKCNH2IDO1CHRNB2
Hydrochloric Acid SCHEMBL9731435 0.74 KDM1A (0.57) KDM1AKDM1BKCNH2CHRNB2CHRNB4
SCHEMBL21999828 0.73 ALDH1A1 (0.34) KDM1AKDM1BKCNH2OPRL1AKR1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4559525-A2 INHIBITING HUMAN INTEGRIN ALPHA4BETA7 Morphic Therapeutic, Inc. (US) 2025-05-28 EP disclosed
EP-4045039-B1 INHIBITING HUMAN INTEGRIN ALPHA4BETA7 MORPHIC THERAPEUTIC INC (US) 2025-04-23 EP disclosed
US-20240174632-A1 INHIBITING HUMAN INTEGRIN (ALPHA-4) (BETA-7) MORPHIC THERAPEUTIC, INC. (US) 2024-05-30 US disclosed
CN-115087444-A Inhibition of human integrin alpha 4 β 7 莫菲克医疗股份有限公司 2022-09-20 CN disclosed
EP-4045039-A1 INHIBITING HUMAN INTEGRIN ALPHA4BETA7 Morphic Therapeutic, Inc. (US) 2022-08-24 EP disclosed
US-11370773-B1 Inhibiting human integrin (alpha-4) (beta-7) MORPHIC THERAPEUTIC, INC. (US) 2022-06-28 US disclosed
WO-2021076890-A1 INHIBITING HUMAN INTEGRIN α4β7 MORPHIC THERAPEUTIC, INC. (US) 2021-04-22 WO disclosed
WO-2021076890-A1 INHIBITING HUMAN INTEGRIN α4β7 MORPHIC THERAPEUTIC, INC. (US) 2021-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11370773-B1 Inhibiting human integrin (alpha-4) (beta-7) ITGB7, ITGB4, ITGA4 KDM1A 3795/4885KDM1B 4098/4885KCNH2 2181/4885
US-20240174632-A1 INHIBITING HUMAN INTEGRIN (ALPHA-4) (BETA-7) ITGB7, ITGB4, ITGA4 KDM1A 3795/4885KDM1B 4098/4885KCNH2 2181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.